Vertex Pharmaceuticals Incorporated (VRTX)

NMS – Real Time Price. Currency in USD

448.29

+13.12 (3.01%)

At close: May 12, 2026, 4:00 PM EDT

447.48

-0.81 (-0.18%)

Pre-market: May 13, 2026, 5:39 AM EDT

11.05.2026

Vertex to Participate in Upcoming May Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026, at 2:35 p.m. ET. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at Bernstein's 42nd Annual Strategic Decisions Con.

08.05.2026

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

08.05.2026

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

06.05.2026

Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy

Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF.

06.05.2026

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-t.

05.05.2026

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.

05.05.2026

VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth

Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.

Videos

22.01.2026

Neutral

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

04.11.2025

Neutral

Committee stocks on the move: Uber and Vertex Pharma

04.08.2025

Positive

Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Press releases

06.05.2026

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

04.05.2026

Vertex Reports First Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 financial guidance. “Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute pain; as well as rapid pipeline progress,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “CASGEVY and J.

01.04.2026

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FD.

09.03.2026

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). The trial met its primary objective. In the interim analysis population, patients treated with povetacicept ach.

Vertex Pharmaceuticals Incorporated (VRTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex to Participate in Upcoming May Investor Conferences

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth

Videos

Press releases

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex Reports First Quarter 2026 Financial Results

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex to Participate in Upcoming May Investor Conferences

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth

Videos

Press releases

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex Reports First Quarter 2026 Financial Results

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Search stocks

Vertex Pharmaceuticals Incorporated (VRTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex to Participate in Upcoming May Investor Conferences

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth

Videos

Press releases

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex Reports First Quarter 2026 Financial Results

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex to Participate in Upcoming May Investor Conferences

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth

Videos

Press releases

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex Reports First Quarter 2026 Financial Results

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy